Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2121 | 2281 | 57.9 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
14 | 37098 | ALZHEIMERS DISEASE//AMYLOID PRECURSOR PROTEIN//BETA AMYLOID |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | BAPINEUZUMAB | Author keyword | 22 | 81% | 1% | 13 |
2 | INTRANEURONAL ABETA | Author keyword | 21 | 90% | 0% | 9 |
3 | SOLANEZUMAB | Author keyword | 19 | 71% | 1% | 15 |
4 | INTRANEURONAL | Author keyword | 18 | 89% | 0% | 8 |
5 | INTRANEURONAL A BETA | Author keyword | 17 | 75% | 1% | 12 |
6 | A BETA IMMUNIZATION | Author keyword | 15 | 88% | 0% | 7 |
7 | N BUD GROSSMAN MEMORY CARE | Address | 14 | 64% | 1% | 14 |
8 | GANTENERUMAB | Author keyword | 11 | 100% | 0% | 6 |
9 | APP TRANSGENIC MICE | Author keyword | 10 | 50% | 1% | 14 |
10 | TG2576 | Author keyword | 10 | 28% | 1% | 30 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BAPINEUZUMAB | 22 | 81% | 1% | 13 | Search BAPINEUZUMAB | Search BAPINEUZUMAB |
2 | INTRANEURONAL ABETA | 21 | 90% | 0% | 9 | Search INTRANEURONAL+ABETA | Search INTRANEURONAL+ABETA |
3 | SOLANEZUMAB | 19 | 71% | 1% | 15 | Search SOLANEZUMAB | Search SOLANEZUMAB |
4 | INTRANEURONAL | 18 | 89% | 0% | 8 | Search INTRANEURONAL | Search INTRANEURONAL |
5 | INTRANEURONAL A BETA | 17 | 75% | 1% | 12 | Search INTRANEURONAL+A+BETA | Search INTRANEURONAL+A+BETA |
6 | A BETA IMMUNIZATION | 15 | 88% | 0% | 7 | Search A+BETA+IMMUNIZATION | Search A+BETA+IMMUNIZATION |
7 | GANTENERUMAB | 11 | 100% | 0% | 6 | Search GANTENERUMAB | Search GANTENERUMAB |
8 | APP TRANSGENIC MICE | 10 | 50% | 1% | 14 | Search APP+TRANSGENIC+MICE | Search APP+TRANSGENIC+MICE |
9 | TG2576 | 10 | 28% | 1% | 30 | Search TG2576 | Search TG2576 |
10 | A BETA OLIGOMERS | 9 | 36% | 1% | 20 | Search A+BETA+OLIGOMERS | Search A+BETA+OLIGOMERS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | A BETA 42 IMMUNIZATION | 80 | 90% | 2% | 35 |
2 | A BETA | 79 | 12% | 28% | 630 |
3 | A BETA42 IMMUNIZATION | 60 | 80% | 2% | 37 |
4 | EFRH PHAGE IMMUNIZATION | 57 | 95% | 1% | 19 |
5 | FIBRILLAR AGGREGATION | 53 | 95% | 1% | 18 |
6 | REDUCES BEHAVIORAL IMPAIRMENT | 50 | 88% | 1% | 23 |
7 | NATURAL OLIGOMERS | 44 | 59% | 2% | 50 |
8 | PROTEIN TRANSGENIC MICE | 36 | 45% | 3% | 60 |
9 | A BETA IMMUNOTHERAPY | 30 | 68% | 1% | 26 |
10 | SECRETED OLIGOMERS | 30 | 45% | 2% | 50 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Immunotherapeutic Approaches for Alzheimer's Disease | 2015 | 4 | 130 | 50% |
Tau aggregation and its interplay with amyloid-beta | 2015 | 5 | 107 | 36% |
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks | 2010 | 334 | 73 | 40% |
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? | 2010 | 157 | 115 | 73% |
Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis | 2015 | 4 | 183 | 38% |
Soluble A ss oligomer production and toxicity | 2012 | 110 | 83 | 49% |
Clinical trials in Alzheimer's disease': immunotherapy approaches | 2012 | 59 | 25 | 80% |
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? | 2014 | 14 | 85 | 75% |
Intracellular amyloid-beta in Alzheimer's disease | 2007 | 652 | 136 | 28% |
Immunotherapy for Alzheimer's disease: hoops and hurdles | 2013 | 26 | 35 | 69% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | N BUD GROSSMAN MEMORY CARE | 14 | 64% | 0.6% | 14 |
2 | ALZHEIMERS DIS NEUROBIOL | 9 | 83% | 0.2% | 5 |
3 | ALZHEIMER PHD | 5 | 55% | 0.3% | 6 |
4 | EXPT DEMENTIA UNIT | 4 | 75% | 0.1% | 3 |
5 | LONGTIME MOL BIOL GENET | 4 | 75% | 0.1% | 3 |
6 | PUBL HLTH CARING SCI MOL GERIATR | 4 | 50% | 0.3% | 6 |
7 | SANDERS BROWN AGING 211 | 4 | 75% | 0.1% | 3 |
8 | MEMORY IMPAIRMENTS NEUROL DISORDERS | 4 | 14% | 1.1% | 24 |
9 | ALEXANDRIA ERSP | 3 | 100% | 0.1% | 3 |
10 | N BUD GROSSMAN | 3 | 100% | 0.1% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000194906 | FAMILIAL DANISH DEMENTIA//BRI2//GLUTAMINYL CYCLASE |
2 | 0.0000175873 | CELLULAR NEUROL//PROTEOPATHY//PRION LIKE AGGREGATION |
3 | 0.0000132357 | 3 4 5 DIMETHYLTHIAZOL 2 YL 2 5 DIPHENYLTETRAZOLIUM BROMIDE//ANAL CHIM CLIN MICROBIOL DIAGNOST MOL//BETA AMYLOID FRAGMENTS |
4 | 0.0000126309 | TUMOR NECROSIS FACTOR CONVERTING ENZYME//KINSMEN NEUROL//FIBRILLAR PLAQUE |
5 | 0.0000113414 | BETA SECRETASE//BACE1//BACE 1 |
6 | 0.0000113356 | PRESENILIN//GAMMA SECRETASE//PRESENILIN 1 |
7 | 0.0000110295 | MEMORY AND LEARNING IMPAIRMENT//ALZHEIMER KOR KUTATOCSOPORT//FLAP PROTEIN |
8 | 0.0000100324 | BETA A4 DEPOSITS//SENILE PLAQUES//NEUROFIBRILLARY TANGLES |
9 | 0.0000097411 | MOL BASIS NEURODEGENERAT//AMYLOID TOXICITY//MOL BASIS NEURODEGENERAT CIMN |
10 | 0.0000097272 | AMYLOID IMAGING//PIB//PITTSBURGH COMPOUND B |